Clinical trials: System Sclerosis
Neuropathic Pain, Multiple Sclerosis
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
The purpose of this study is to determine whether nabilone (Cesamet) when used as an adjunctive agent with gabapentin (Neurontin) provides significantly improved pain relief over gabapentin alone for the management of neuropathic…
- Trial name
- NCT00480181
- Testing
- nabilone
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Manitoba
Stroke, Multiple Sclerosis
Improving Social Cognition and Social Behaviour in Various Brain Disorders
Impairments in aspects of social cognition are disorder-transcending: these have been demonstrated in various neurological disorders, such as traumatic brain injury (TBI), stroke, brain tumours (both low grade glioma's and…
- Conditions
- Stroke, Multiple Sclerosis, Brain Tumor
- Trial name
- T-ScEmo4ALL (NCT06330298)
- Testing
- Treatment social cognition and emotion regulation (T-ScEmo)
- Where
- 2 sites in Netherlands
- Volunteers
- 84 people
- Sponsor
- University Medical Center Groningen
Scleroderma, Systemic
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
ASSIST I was the first randomized trial in patients with scleroderma to not just slow disease progression but rather actually reverse it.
- Trial name
- DIScl2011 (NCT01445821)
- Testing
- Peripheral Blood Stem Cells, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient
The aim of this study is the comparison between the effects of supplementation with vitamin A (retinyl palmitate) or placebo for 6 months on gene expression of T CD4+ lymphocyte in multiple sclerotic patient.
- Trial name
- MS (NCT01407211)
- Testing
- vitamin A
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Tehran University of Medical Sciences
Tuberous Sclerosis
A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
This is a single centre, two-arm, individually randomised, Phase II, double- blind, placebo-controlled trial of RAD001 (Everolimus) versus placebo in the treatment of neurocognitive problems in patients with tuberous sclerosis…
- Trial name
- TRON (NCT01954693)
- Testing
- Everolimus (RAD001)
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Cardiff University
Relapsing Remitting Multiple Sclerosis
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple…
- Trial name
- ROS-MS (NCT06663111)
- Testing
- Blood samples for PK
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis, Covid19
MS Relapses During COVID-19 Pandemic
Throughout the COVID-19 pandemic, and to our knowledge there have been no studies looking systematically at the occurrence of MS relapses and their subsequent management, during the peak of the first wave of the pandemic.
- Conditions
- Multiple Sclerosis, Covid19, Relapsing Remitting Multiple Sclerosis
- Trial name
- NCT04858763
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Neurodegenerative Diseases, Cognitive Decline
The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive Impairment
VESPA 2.0 is based on an integrative and ecological approach used for the treatment of cognitive dysfunction in patients with MCI or other neurodegenerative disorders.
- Conditions
- Neurodegenerative Diseases, Cognitive Decline, Parkinson Disease Dementia, Alzheimer Disease
- Trial name
- NCT06281314
- Testing
- Vespa software
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Systemic Sclerosis
Open-Label Study of Oral Treprostinil in Digital Ulcers
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects…
- Trial name
- DISTOL-EXT (NCT00848107)
- Testing
- treprostinil diethanolamine
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- United Therapeutics
Multiple Sclerosis
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in…
- Trial name
- Frexcite (NCT07325292)
- Testing
- Frexalimab, MRI contrast-enhancing preparations
- Where
- 68 sites in United States, Belgium and 5 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Hemiplegia, Spasticity
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
This trial is part of the spastiCRYO clinical research project. The primary objective of this clinical trial is to test the hypothesis: "Upper limb nerve cryoneurolysis is non inferior to the usual care and has therapeutic add…
- Conditions
- Hemiplegia, Spasticity, Shoulder Spasticity, Shoulder Stiffness
- Trial name
- spastiCRYO-UL (NCT06782464)
- Testing
- Treatment
- Where
- Luxembourg
- Volunteers
- 50 people
- Sponsor
- Centre National de Rééducation Fonctionnelle et de Réadaptation
Pirfenidone, Connective Tissue Diseases
Efficacy and Safety of Pirfenidone in CTD-ILD
A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months.
- Conditions
- Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease
- Trial name
- NCT05505409
- Testing
- Pirfenidone, glucocorticoid and immunosuppressant
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Chronic Intestinal Pseudo-obstruction
Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial
The objective of the study is to investigate efficacy and safety of rifaximin (L-105) in patients with chronic idiopathic intestinal pseudo-obstruction(CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO)…
- Trial name
- NCT04118699
- Testing
- Rifaximin oral tablet
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Yokohama City University
Systemic Sclerosis
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
Systemic sclerosis (SSc) is a complex systemic autoimmune disease with variable phenotype and prognosis. Autoantibodies are important diagnostic biomarkers in SSc. More than 90% of patients with SSc had anti-nuclear antibodies.
- Trial name
- SCLERONAB (NCT06412614)
- Testing
- disease phenotype
- Where
- 14 sites in France
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Familial Amyotrophic Lateral Sclerosis
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.
- Trial name
- NCT01083667
- Testing
- Pyrimethamine
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
Relapsing Remitting Multiple Sclerosis
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
The purpose of this study is to explore immunomodulatory and immunosuppressive mechanisms of action of fingolimod in patients with Relapsing remitting multiple Sclerosis to collect data on biomarkers after initiation of…
- Trial name
- BiobankII (NCT01755871)
- Testing
- Fingolimod
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis
Under and Over Rehabilitation Study
Multiple Sclerosis (MS) is a progressive neurological condition of the central nervous system for which there is no cure. Symptoms include motor and sensory dysfunction, bladder and bowel dysfunction as well as speech and…
- Trial name
- NCT04490044
- Testing
- Under & Over rehabilitation tool
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Queen Mary University of London
Amyotrophic Lateral Sclerosis
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the…
- Trial name
- REViVALS-1B (NCT05176093)
- Testing
- Engensis
- Where
- 2 sites in United States, South Korea
- Volunteers
- 8 people
- Sponsor
- Helixmith Co., Ltd.
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Autoimmune Diseases, Immune System Diseases
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with mesenchymal stem cells from adipose tissue, administered intravenously in patients with secondary progressive multiple…
- Conditions
- Autoimmune Diseases, Immune System Diseases, Demyelinating Diseases, Nervous System Diseases
- Trial name
- NCT01056471
- Testing
- Autologous mesenchymal stem cells from adipose tissue.
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.